Onxeo S.A.
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Market Cap & Net Worth: Onxeo S.A. (0NWK)
Onxeo S.A. (LSE:0NWK) has a market capitalization of $6.99 Million (€6.81 Million) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #29588 globally and #461 in its home market, demonstrating a -5.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Onxeo S.A.'s stock price €0.13 by its total outstanding shares 50647100 (50.65 Million).
Onxeo S.A. Market Cap History: 2026 to 2026
Onxeo S.A.'s market capitalization history from 2026 to 2026. Data shows growth from $6.99 Million to $6.99 Million (0.00% CAGR).
Onxeo S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Onxeo S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0NWK by Market Capitalization
Companies near Onxeo S.A. in the global market cap rankings as of March 18, 2026.
Key companies related to Onxeo S.A. by market ranking:
- Argo Properties NV (TA:ARGO): Ranked #29579 globally with a market cap of $7.87 Million USD ( ILA2.94 Billion ILA).
- FRIWO AG (F:CEA): Ranked #29580 globally with a market cap of $7.87 Million USD ( €7.67 Million EUR).
- Tong Hua Holding Public Company Limited (BK:TH): Ranked #29589 globally with a market cap of $7.86 Million USD ( ฿272.51 Million THB).
- Freightos Limited Warrants (NASDAQ:CRGOW): Ranked #29590 globally with a market cap of $7.86 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #29579 | Argo Properties NV | TA:ARGO | $7.87 Million | ILA12790.00 |
| #29580 | FRIWO AG | F:CEA | $7.87 Million | €5.05 |
| #29589 | Tong Hua Holding Public Company Limited | BK:TH | $7.86 Million | ฿0.46 |
| #29590 | Freightos Limited Warrants | NASDAQ:CRGOW | $7.86 Million | $0.23 |
Onxeo S.A. Historical Marketcap From 2026 to 2026
Between 2026 and today, Onxeo S.A.'s market cap moved from $6.99 Million to $ 6.99 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.99 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Onxeo S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.99 Million USD |
| MoneyControl | $6.99 Million USD |
| MarketWatch | $6.99 Million USD |
| marketcap.company | $6.99 Million USD |
| Reuters | $6.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.